Reverse transcription, also known as cDNA synthesis from an RNA template, is carried out by reverse transcriptases (RTs), an enzyme. To direct the synthesis of the first strand cDNA, reverse transcriptases (RTs) combine an RNA template with a brief primer complementary to the 3' end of the RNA.
Reverse transcriptase, an HIV enzyme, is blocked by nucleoside reverse transcriptase inhibitors (NRTIs). HIV reverse transcriptase is bound to and blocked by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Reverse transcription is the process by which HIV turns RNA into DNA. HIV cannot replicate when reverse transcriptase and reverse transcription are blocked.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V54257 | (+)-Dihydrocalanolide A (DHCal A; NSC 678323) | 183904-53-2 | (+)-Dihydrocalanolide A (DHCal A; NSC 678323) is an orally bioavailable, non-nucleoside reverse transcriptase inhibitor. |
|
V9903 | Abacavir | 136470-78-5 | Abacavir (formerly also known as ABC, or 1592U89; trade names: Ziagen; Epzicom) is a commonly used nucleoside analogue of the NRTI class with potent antiviral activity against HIV-1. |
|
V1826 | Abacavir sulfate (ABC) | 188062-50-2 | Abacavir (formerly also known as ABC, or 1592U89; trade names: Ziagen; Epzicom) is a commonly used nucleoside analogue of the NRTI class with potent antiviral activity against HIV-1. |
|
V10325 | Adefovir (GS-0393) | 106941-25-7 | Adefovir (formerly known as PMEA and GS-0393; trade names Preveon and Hepsera) is a potent DNA polymerase inhibitor with the potential for the treatment of HBV infection. |
|
V1815 | Adefovir Dipivoxil (GS 0840) | 142340-99-6 | Adefovir Dipivoxil (also known as GS 0840 and GS-0840; trade names Preveon and Hepsera), the dipivoxil formulation of adefovir, is a reverse transcriptase inhibitor, used in the treatment of chronic hepatitis B virus (HBV). |
|
V2865 | BMS-538203 | 543730-41-2 | BMS-538203 is a novel and highly efficient HIV integrase inhibitor that is being developed as an antiviral agent. |
|
V1833 | BMS-707035 | 729607-74-3 | BMS-707035 is a novel, potent, specific, and reversible inhibitor of HIV-I integrase (IN) with IC50 of 15 nM. |
|
V1835 | Cabotegravir (GSK744; GSK1265744) | 1051375-10-0 | Cabotegravir (formerly GSK744; GSK1265744; GSK-744; GSK-1265744;Rekambys; Cabenuva) is a potent, orally bioavailable and long-acting inhibitor of HIV integrase approved in 2020 for the treatment and prevention of HIV infection. |
|
V1827 | Dapivirine (TMC120) | 244767-67-7 | Dapivirine (also known as TMC120) is a potent non-nucleoside inhibitor for HIV reverse transcriptase with IC50 of 24 nM, itinhibits a broad panel of HIV-1 isolates from different classes, inclucing a wide range of NNRTI-resistant isolates. |
|
V5187 | Delavirdine mesylate (U-90152) | 147221-93-0 | Delavirdine mesylate (U-90152) is a potent non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI) of HIV-1 used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. |
|
V1817 | Didanosine (Videx) | 69655-05-6 | Didanosine (also known as 2′,3′-dideoxyinosine, ddI, DDI; trade names Videx and Videx EC) is a potent reverse transcriptase inhibitor with an IC50 of 0.49 μM. |
|
V1832 | Dolutegravir (GSK1349572) | 1051375-16-6 | Dolutegravir (formerly also known as GSK1349572; GSK-1349572;Tivicay) is a novel, potent and orally bioavailable two-metal-binding HIV integrase inhibitor approved to treating HIV infections. |
|
V2641 | Efavirenz | 154598-52-4 | Efavirenz (also called Sustiva, Stocrin, DMP-266, DMP 266), a non-nucleoside reverse transcriptase inhibitor (NNRTI),is a highly potent and specific inhibitor of human immunodeficiency virus type 1 reverse transcriptase with Ki value of 2.93nM. |
|
V1831 | Elvitegravir (GS-9137, JTK-303) | 697761-98-1 | Elvitegravir (also known as GS-9137, JTK-303,D06677 or EVG) is a potentHIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively. |
|
V1813 | Emtricitabine (BW1592) | 143491-57-0 | Emtricitabine (BW1592; FTC; Coviracil; Emtriva; Racivir) is a potent nucleoside reverse transcriptase inhibitor (NRTI) with anEC50of 0.01 µM and has been used for the treatment of both human immunodeficiency virus (HIV) and hepatitis B virus. |
|
V1814 | Entecavir Hydrate (BMS200475) | 209216-23-9 | Entecavir hydrate (also known as SQ-34676 and BMS-200475), monohydrated form of entecavir and anti-hepatitis B virus (HBV) agent,is a novel deoxyguanine nucleoside analogue and areverse transcriptase inhibitor. |
|
V1828 | Etravirine (R165335; TMC125) | 269055-15-4 | Etravirine (formerly TMC-125; R-165335) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. |
|
V1829 | Foscarnet Sodium | 63585-09-1 | Foscarnet Sodium (also known as Phosphonoformate),an antiherpesvirus agent,inhibits viral RNA polymerases, reverse transcriptase, and DNA polymerases through noncompetitive inhibition with dNTPs. |
|
V54261 | Inophyllum B ((+)-Inophyllum B) | 41135-06-2 | Inophyllum B ((+)-Inophyllum B) is a potent HIV reverse transcriptase inhibitor (antagonist) with IC50 of 38 nM. |
|
V1821 | Lamivudine (BCH-189) | 134678-17-4 | Lamivudine (formerly also known as GR109714X; 3TC, Heptovir, BCH-189; trade names: Epivir, Zeffix) is a potent nucleoside analog reverse transcriptase (NRTI) inhibitor, which has been approved for treatment of chronic HBV and HIV/AIDS. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
